Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of a Family Caregiver Palliative Care Intervention

NCT01846520 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01846520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01846520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Lead sponsor
City of Hope Medical Center
Phase
Not applicable
Overall status
Completed
Start date
October 29, 2013
Completion date
May 23, 2019
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subject, localized transitional cell cancer of the renal pelvis and ureter, metastatic transitional cell cancer of the renal pelvis and ureter, psychosocial effects of cancer and its treatment, recurrent bladder cancer, recurrent cervical cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent pancreatic cancer, recurrent rectal cancer, recurrent renal cell cancer, recurrent transitional cell cancer of the renal pelvis and ureter, recurrent urethral cancer, recurrent uterine sarcoma, regional transitional cell cancer of the renal pelvis and ureter, stage ii bladder cancer, stage ii renal cell cancer, stage ii urethral cancer, stage iia cervical cancer, stage iia colon cancer, stage iia gastric cancer, stage iia lung carcinoma, stage iia ovarian epithelial cancer, stage iia ovarian germ cell tumor, stage iia pancreatic cancer, stage iia rectal cancer, stage iia uterine sarcoma, stage iib cervical cancer, stage iib colon cancer, stage iib gastric cancer, stage iib lung carcinoma, stage iib ovarian epithelial cancer, stage iib ovarian germ cell tumor, stage iib pancreatic cancer, stage iib rectal cancer, stage iib uterine sarcoma, stage iic colon cancer, stage iic ovarian epithelial cancer, stage iic ovarian germ cell tumor, stage iic rectal cancer, stage iii bladder cancer, stage iii pancreatic cancer, stage iii renal cell cancer, stage iii urethral cancer, stage iiia cervical cancer, stage iiia colon cancer, stage iiia gastric cancer, stage iiia lung carcinoma, stage iiia ovarian epithelial cancer, stage iiia ovarian germ cell tumor, stage iiia rectal cancer, stage iiia uterine sarcoma, stage iiib cervical cancer, stage iiib colon cancer, stage iiib gastric cancer, stage iiib lung carcinoma, stage iiib ovarian epithelial cancer, stage iiib ovarian germ cell tumor, stage iiib rectal cancer, stage iiib uterine sarcoma, stage iiic colon cancer, stage iiic gastric cancer, stage iiic ovarian epithelial cancer, stage iiic ovarian germ cell tumor, stage iiic rectal cancer, stage iiic uterine sarcoma, stage iv bladder cancer, stage iv gastric cancer, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor, stage iv pancreatic cancer, stage iv renal cell cancer, stage iv urethral cancer, stage iva cervical cancer, stage iva colon cancer, stage iva rectal cancer, stage iva uterine sarcoma, stage ivb cervical cancer, stage ivb colon cancer, stage ivb rectal cancer, stage ivb uterine sarcoma, ureter cancer